Bonesupport Holding AB
STO:BONEX
Bonesupport Holding AB
EPS (Diluted)
Bonesupport Holding AB
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Bonesupport Holding AB
STO:BONEX
|
EPS (Diluted)
kr2
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Biogaia AB
STO:BIOG B
|
EPS (Diluted)
kr3
|
CAGR 3-Years
22%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
|
Vitrolife AB
STO:VITR
|
EPS (Diluted)
kr3
|
CAGR 3-Years
8%
|
CAGR 5-Years
1%
|
CAGR 10-Years
14%
|
|
|
Probi AB
STO:PROB
|
EPS (Diluted)
kr0
|
CAGR 3-Years
-48%
|
CAGR 5-Years
-33%
|
CAGR 10-Years
-7%
|
|
|
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
|
EPS (Diluted)
kr11
|
CAGR 3-Years
9%
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
|
|
BioArctic AB
STO:BIOA B
|
EPS (Diluted)
-kr2
|
CAGR 3-Years
-14%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Bonesupport Holding AB
Glance View
Bonesupport Holding AB, a Swedish company, has carved a niche for itself in the intricate world of orthopedic treatments and regenerative medicine. Founded in 1999, the company's journey is rooted in innovation and development of injectable bio-ceramic bone graft substitutes, primarily aimed at addressing bone voids and other skeletal maladies. The cornerstone of their business is the proprietary CERAMENT platform, which combines biocompatible, synthetic materials with a unique ability to promote bone healing and integration. By offering solutions that are resorbable and can enhance the regrowth of natural bone, Bonesupport targets clinicians and professionals in orthopedics, trauma, and spine surgery, offering them alternatives to traditional bone grafting methods. The company's products, including CERAMENT BONE VOID FILLER, CERAMENT G, and CERAMENT V, differentiate themselves by also being antibiotic-eluting—allowing for the simultaneous treatment of bone diseases and infection mitigation. Bonesupport's revenue models revolve around both direct sales and leveraging distribution partnerships in key markets, including Europe, the United States, and emerging regions. The company channels substantial investments into research and development, seeking to broaden the clinical applications of their technologies thus driving adoption in the market. They benefit from a growing interest in minimally invasive treatments among healthcare providers, who aim to enhance patient outcomes while also controlling costs. By continuing to expand its product portfolio and advancing clinical evidence, Bonesupport maintains a competitive edge in skeletal health, translating innovation and efficacy into profitability and market growth. This strategic pursuit of advanced bone treatment technologies underscores their role in transforming standard medical practices, ensuring they remain at the forefront of bone health solutions.
See Also
What is Bonesupport Holding AB's EPS (Diluted)?
EPS (Diluted)
2
SEK
Based on the financial report for Dec 31, 2024, Bonesupport Holding AB's EPS (Diluted) amounts to 2 SEK.
What is Bonesupport Holding AB's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 1Y
-46%
Over the last year, the EPS (Diluted) growth was -46%.
You don't have any saved screeners yet